Celcuity (NASDAQ:CELC) Earns Buy Rating from Analysts at Stifel Nicolaus

Equities research analysts at Stifel Nicolaus started coverage on shares of Celcuity (NASDAQ:CELC) in a research note issued on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $30.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 130.06% from the stock’s current price.

CELC has been the topic of a number of other reports. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 target price on shares of Celcuity in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a report on Monday, May 19th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Celcuity presently has a consensus rating of “Buy” and a consensus target price of $28.40.

Celcuity Stock Performance

NASDAQ:CELC opened at $13.04 on Tuesday. The firm has a 50-day moving average of $11.40 and a two-hundred day moving average of $11.25. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.61 and a quick ratio of 6.61. The stock has a market cap of $493.82 million, a P/E ratio of -4.30 and a beta of 0.45. Celcuity has a 1-year low of $7.58 and a 1-year high of $19.77.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.09. On average, research analysts expect that Celcuity will post -2.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

Large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. lifted its position in shares of Celcuity by 49.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after acquiring an additional 1,132 shares during the period. GAMMA Investing LLC grew its holdings in Celcuity by 1,237.4% during the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company’s stock worth $131,000 after acquiring an additional 1,225 shares during the last quarter. Gagnon Securities LLC grew its holdings in Celcuity by 3.5% during the 1st quarter. Gagnon Securities LLC now owns 54,310 shares of the company’s stock worth $549,000 after acquiring an additional 1,831 shares during the last quarter. Corebridge Financial Inc. increased its position in Celcuity by 12.9% in the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company’s stock valued at $213,000 after acquiring an additional 1,858 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Celcuity by 22.3% in the fourth quarter. JPMorgan Chase & Co. now owns 14,683 shares of the company’s stock worth $192,000 after acquiring an additional 2,676 shares during the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.